Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AHG vs SNYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SNYR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

SNYR Overall Winner 6-Pillar Tally: AHG 2 – 3 SNYR (1 Tie) Matrix Metrics: AHG 5 – 5 SNYR

As of Nov 20, 2026, Synergy CHC Corp. (SNYR) is the stronger overall head-to-head candidate over Akso Health Group ADS (AHG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). AHG carries a Unified Composite Score of 38.2/100 (SELL) at $1.26 (N/M Forward P/E, -28.9% operating margin), whereas SNYR carries 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin).

  • Growth vs. Quality Trade-Off: SNYR earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. AHG 38.2/100 SELL) and -0.86β · 868% Vol risk profile, whereas AHG leads top-line expansion (-12.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHG vs SNYR
AHG NASDAQ
Akso Health Group ADS
Services-Business Services, Nec
$1.26
-1.56% 1D
Market Cap $1.1B
TTM Revenue $14M
Forward P/E N/M
Beta / 30D Vol 0.38β · 101% Vol
Unified Composite Score
38.2 / 100 SELL
Tech 20.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.6 · SMA20: $1.30 · SMA50: $1.14
SNYR NASDAQ Head-to-Head Winner
Synergy CHC Corp. Common Stock
Medicinal Chemicals & Botanical Products
$0.09
-67.02% 1D
Market Cap $4.1M
TTM Revenue $28M
Forward P/E 0.6x
Beta / 30D Vol -0.86β · 868% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 55.0 Fund 39.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $0.11 · SMA50: $0.14

6-Pillar Scorecard Institutional Category Breakdown (AHG 2 – 3 SNYR)

Columns: Metric · AHG · SNYR
1. Valuation Multiples SNYR
Forward P/E N/M 0.6x
Trailing P/E N/M 0.6x
PEG Ratio N/M N/M
EV / Revenue 79.3x 0.1x
2. Growth & Scale AHG
Revenue Growth (YoY) -12.9% -32.8%
Earnings Growth (YoY) +0.0% -90.6%
TTM Revenue (USD) $14M $28M
Market Cap $1.1B $4.1M
3. Profitability & Quality SNYR
Gross Margin -0.1% 65.4%
Operating Margin -28.9% -10.3%
Net Profit Margin -135.0% -57.0%
Return on Equity (ROE) -9.8% -361.1%
4. Balance Sheet & Cash Flow AHG
Cash Generation (TTM) -$1.6M EBITDA -$3.8M
Cash Flow Margin -11.8% EBITDA Mgn -13.7%
Net Cash / Leverage $0.21 Book/Sh · -9.8% ROE -361.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SNYR
OpEx & R&D Intensity 28.8% of Rev ($4.0M) 75.7% of Rev ($21M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Distribution Operator Medical Distribution Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHG (5) vs SNYR (5)
Institutional Metric AHG SNYR Criterion Row Edge
Market Capitalization
Scale
$1.1B $4.1M Larger Scale AHG
Trailing P/E Ratio
Valuation
N/M 0.6x Lower Multiple SNYR
Forward P/E Ratio
Valuation
N/M 0.6x Lower Multiple SNYR
Revenue Growth (YoY)
Growth
-12.9% -32.8% Higher Growth AHG
Operating Margin (TTM)
Profitability
-28.9% -10.3% Higher Margin SNYR
Net Profit Margin
Profitability
-135.0% -57.0% Higher Margin SNYR
Return on Equity (ROE)
Capital Efficiency
-9.8% -361.1% Higher ROE AHG
52-Week Range Position
Momentum
32% ($1–$2) 1% ($0–$3) Stronger Trend AHG
Beta / 30D Volatility
Risk Regime
0.38β · 101% Vol -0.86β · 868% Vol Lower Realized Risk AHG
Unified Institutional Score
Composite Signal
38.2 / 100 (SELL) 48.9 / 100 (HOLD) Higher Composite SNYR
Trailing 12M Revenue (USD)
Operating Scale
$14M $28M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-0.1% 65.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 79.3x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.6M EBITDA ($0.21 Book/Sh · -9.8% ROE) -$3.8M (-361.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SNYR +11.95 pp
AHG: -28.23% · SNYR: -16.28%
3M Horizon AHG +15.35 pp
AHG: -38.02% · SNYR: -53.37%
6M Horizon AHG +25.61 pp
AHG: -67.53% · SNYR: -93.14%
1Y Horizon AHG +46.46 pp
AHG: -48.98% · SNYR: -95.44%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AHG vs SNYR. Trailing 12-month operating profitability (AHG -28.9% vs SNYR -10.3%) and valuation multiples (AHG N/M vs SNYR 0.6x Forward P/E) are benchmarked directly in Pillar 4 below.

AHG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14M
Gross Margin-0.1%
Op. Margin-28.9%
ROE / Fwd P/E-9.8% · N/M
SNYR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28M
Gross Margin65.4%
Op. Margin-10.3%
ROE / Fwd P/E-361.1% · 0.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AHG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SNYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHG Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $1.1B market capitalization and -28.9% operating margin.
OpEx & R&D Reinvestment 28.8% of Rev ($4.0M)
90D Engineering Disclosures 0 Published
SNYR Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $4.1M market capitalization and -10.3% operating margin.
OpEx & R&D Reinvestment 75.7% of Rev ($21M)
90D Engineering Disclosures 0 Published

Investor FAQ AHG vs SNYR Key Questions & Quantitative Answers

As of Nov 20, 2026, Synergy CHC Corp. (SNYR) is the stronger overall head-to-head candidate over Akso Health Group ADS (AHG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). AHG carries a Unified Composite Score of 38.2/100 (SELL) at $1.26 (N/M Forward P/E, -28.9% operating margin), whereas SNYR carries 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin). Growth vs. Quality Trade-Off: SNYR earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. AHG 38.2/100 SELL) and -0.86β · 868% Vol risk profile, whereas AHG leads top-line expansion (-12.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

AHG leads the Growth & Scale pillar: AHG posts -12.9% YoY revenue growth and +0.0% YoY earnings growth on $14M TTM revenue (-0.1% gross margin, -28.9% operating margin), compared with SNYR at -32.8% YoY revenue growth and -90.6% YoY earnings growth on $28M TTM revenue (65.4% gross margin, -10.3% operating margin). On trailing 12-month operating scale, AHG generates $14M in USD-normalized revenue versus $28M for SNYR. In operating R&D and SG&A reinvestment, AHG deploys 28.8% of Rev ($4.0M) (0 90-day corporate R&D disclosures) versus 75.7% of Rev ($21M) (0 disclosures) for SNYR.

SNYR screens cheaper on headline valuation multiples. AHG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 79.3x EV/Revenue (-11.8% EBITDA margin), whereas SNYR trades at 0.6x Forward P/E, 0.6x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-13.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHG (-9.8% ROE) versus SNYR (-361.1% ROE) capital efficiency.

In options market volatility and institutional positioning, AHG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.38β · 101% Vol realized risk). By comparison, SNYR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.86β · 868% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.